Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: RETRACTED ARTICLE: LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2

Fig. 2

LNCAROD knockdown inhibits HCC malignancy both in vitro and in vivo. A CCK8, B colony formation, C migration and invasion, D epithelial-to-mesenchymal transition marker expression assays in SNU-449 and HCC-LM3 cells transfected with shCtr or shLNCAROD. E-G CCK-8, colony formation, and apoptosis analysis of cells in (A-D) in the presence of the indicated concentrations of 5-FU. H Representative images of the xenograft tumors of shLNCAROD-transfected HCC-LM3 cells in nude mice following 5-FU treatment. I Tumor growth curves of shCtr- or shLNCAROD-transfected HCC-LM3 cells in nude mice after 5-FU treatment during the indicated weeks. J Ki67 expression in shCtr- or shLNCAROD-transfected HCC-LM3 cells in nude mice after 5-FU treatment. K Table summarizing the results of lung metastasis. L Number of metastatic foci per section in lungs from nude mice injected with shLNCAROD and/or 5-FU. Data are shown as the mean ± SD. *P < 0.05; **P < 0.01

Back to article page